Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall
- Paternal Microbiome Perturbations Impact Offspring Fitness
- New Report Casts Doubt on Maradona’s Cause of Death and Rocks Manslaughter Case
- Chinese academician unable to provide the exact source of liver transplants
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
- Aspirin Found Ineffective in Improving Recurrence Risk or Survival Rate of Breast Cancer Patients
- Child Products from Aliexpess and Temu Contain Carcinogens 3026x Over Limit
Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall.
Moderna hopes to launch a vaccine against Covid-19, influenza and respiratory syncytial virus (a common respiratory virus) as early as fall 2023, Chief Executive Stephane Bancel said on Monday. The three-in-one vaccine booster shot.
Moderna’s chief executive, Stéphane Bancel, said the company’s goal is to have the compound vaccine available in multiple countries in the next 18 months or so.
In addition to immunizing people against Covid-19 and the flu virus, the vaccine will target respiratory syncytial virus (RSV), a common virus that often causes cold-like symptoms.
“Our goal is to develop a booster shot with only one dose per year. If people don’t want to get 2 or 3 doses of vaccine every winter, they just want to get one dose, so there will be no compliance issues.” Bancel in the world Speaking at a virtual roundtable of the World Economic Forum.
In the best-case scenario, the compound vaccine would be available in some countries by the fall of 2023, Bancel said.
He said that the RSV project is in the third phase of trials, which is the final stage of human testing; while the influenza project is in the second phase of trials and is expected to enter the third phase of trials in the second quarter of this year.
Bancel also said that Moderna’s vaccine candidate for the mutated virus Omicron has basically been developed and is about to enter the clinical stage.
The company expects to share data with regulators around March, he added.
Like Pfizer and its partner BioNTech, Moderna has developed a Covid-19 vaccine using advanced messenger RNA (mRNA) technology that differs from traditional vaccines, and has achieved impressive results. The company and its shareholders hope to see more growth from mRNA technology in the future.
Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.